Key points are not available for this paper at this time.
Participants would trade PFS for changes in short-term side effects and long-term side effects, although preference heterogeneity existed. Lung cancer treatments that offer less PFS but also less severe side effects might be acceptable to some patients.
Janssen et al. (Mon,) studied this question.